argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-09-18 08:27 |
argenx announces launch of proposed public offering in the United States
|
English | 258.5 KB | ||
| 2018-09-17 08:48 |
argenx reports positive topline results from Phase 2 proof-of-concept trial of …
|
English | 117.5 KB | ||
| 2018-09-06 08:27 |
argenx doses first patient in global Phase 3 registration trial of efgartigimod…
|
English | 16.6 KB | ||
| 2018-08-29 08:36 |
argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regula…
|
English | 15.2 KB | ||
| 2018-08-22 08:18 |
argenx announces that AbbVie has exercised its exclusive option to license ARGX…
|
English | 153.9 KB | ||
| 2018-08-10 08:30 |
argenx to Present at 2018 Wedbush PacGrow Healthcare Conference
|
English | 84.5 KB | ||
| 2018-08-02 08:21 |
argenx reports second quarter business update and half-year 2018 financial resu…
|
English | 384.7 KB | ||
| 2018-07-26 08:34 |
argenx to host conference call & webcast to report second quarter business upda…
|
English | 91.7 KB | ||
| 2018-07-25 07:52 |
argenx announces publication of full data from Phase 1 healthy volunteer study …
|
English | 151.3 KB | ||
| 2018-07-17 08:32 |
argenx receives milestone payment from strategic collaboration with Shire
|
English | 148.4 KB | ||
| 2018-06-28 08:16 |
argenx receives second preclinical milestone payment under its development agre…
|
English | 14.6 KB | ||
| 2018-06-20 08:34 |
argenx reports interim data from first cohort of Phase 2 proof-of-concept clini…
|
English | 108.7 KB | ||
| 2018-06-14 08:27 |
argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneou…
|
English | 17.5 KB | ||
| 2018-06-12 08:38 |
argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2…
|
English | 90.0 KB | ||
| 2018-06-06 08:32 |
argenx selected for BEL 20 Index
|
Dutch | 147.8 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
